Clinical and economic analysis of administering ustekinumab(stelara) to patients with severe psoriasis

Abstract


There was a clinical and economic study of ustekinumab (stelara) as compared to etanercept (enbrel), infliximab
(remicade) and adalimumab (humira) for treating patients with severe psoriasis. The clinical efficacy and safety of the
biological drugs were analyzed, and estimated costs for their application as well as cost/efficacy ratio and cost efficacy
increment were calculated. Advantages of ustekinumab vs. etanercept were demonstrated: the costs per one patient
with severe psoriasis turned out to be less with the achieved positive effect. When the cost/efficacy ratio was calculated,
the economic advantages of ustekinumab vs. infliximab were established beginning with Weeks 24-28 of the therapy
(according to the results of individual studies, as early as beginning with Week 10 of the therapy). The economic
advantage of ustekinumab vs. adalimumab increases by Week 52 of the therapy. The calculations of the cost efficacy
increment proved that ustekinumab was more efficient than infliximab both in the short (Weeks 10-12 of the therapy)
and long run (Weeks 50-52) and more efficient than adalimumab in the long run (Week 52 of the therapy).

References

  1. Клинические рекомендации по терапии псориаза - новый проект в России. Мед. вестн. 2008;. 24-25: 451-452. URL: http:// medvestnik.ru/archive/2008/24/1378.html.
  2. Griffiths Christopher E.M., Strober B. E., Kerkhof P. et al. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. N Engl J Med 2010; 362: 118-28.
  3. Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; Oct; 51 (4): 534-42.
  4. Leonardi C., Kimball A.B., Papp K.A. et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; May 17; 371 (9625): 1665-74.
  5. Menter А., Steven R. et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2006; 14.
  6. Menter А., Tyring S. K. et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
  7. Papp K.A., Langley R.G., Lebwohl M. et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; May 17; 371 (9625): 1675-84.
  8. Reich K., Nestle F.O., Papp K. et al. Infliximab induction and maintenance therapy for moderate- to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; Oct 15-21; 366 (9494): 1367-74.
  9. Saurat J.-H., Stingl G. et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Brit J Dermatol 2008; 158: 558-566.
  10. Leonardi С. Clinical Study Report: 52-Week. Protocol C0743T08. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis. PHOENIX 1. 09 Oct 2007.
  11. Reich К. Clinical Study Report: 52-Week. Protocol C0743T09. A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis. PHOENIX 2. 20 Jun 2008.

Statistics

Views

Abstract - 600

PDF (Russian) - 449

PlumX

Article Metrics

Metrics Loading ...

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Sura M.V., Avksent'eva M.V., Omel'yanovskiy V.V., Kubanova A.A., Sura M.V., Avksentiyeva M.V., Omeliyanovsky V.V., Kubanova A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies